Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer

BACKGROUND: A small proportion of patients with non-small cell lung cancer (NSCLC) experience objective clinical benefit after neoadjuvant programmed cell death 1 (PD-1) blockade. A neoadjuvant therapeutic regimen combining immune checkpoint blockade with chemotherapy might improve the treatment eff...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Transl Lung Cancer Res
Autors principals: Chen, Yulong, Yan, Bo, Xu, Feng, Hui, Zhenzhen, Zhao, Gang, Liu, Jie, Zhang, Huan, Zeng, Ziqing, Zhang, Ran, Provencio, Mariano, Ren, Xiubao, You, Jian
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2021
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8182703/
https://ncbi.nlm.nih.gov/pubmed/34164269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-21-329
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars